Male Breast Cancer Completed Phase 2 Trials for Pazopanib (DB06589)

IndicationStatusPhase
DBCOND0028546 (Male Breast Cancer)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00509587Pazopanib in Treating Patients With Recurrent or Metastatic Breast CancerTreatment